Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 2/2019

01-06-2019 | Glioblastoma | Clinical Study

Racial/ethnic differences in survival for patients with gliosarcoma: an analysis of the National cancer database

Authors: James M. Wright, Tiffany R. Hodges, Christina Huang Wright, Haley Gittleman, Xiaofei Zhou, Kelsey Duncan, Carol Kruchko, Andrew Sloan, Jill S. Barnholtz-Sloan

Published in: Journal of Neuro-Oncology | Issue 2/2019

Login to get access

Abstract

Purpose

Gliosarcoma is characterized by the World Health Organization as a Grade IV malignant neoplasm and a variant of glioblastoma. The association of race and ethnicity with survival has been established for numerous CNS malignancies, however, no epidemiological studies have reported these findings for patients with gliosarcoma. The aim of this study was to examine differences by race and ethnicity in overall survival, 30-day mortality, 90-day mortality, and 30-day readmission.

Methods

Data were obtained by query of the National Cancer Database (NCDB) for years 2004–2014. Patients with gliosarcoma were identified by International Classification of Diseases for Oncology, Third Edition (ICD-O-3)—Oncology morphologic code 9442/3 and topographical codes C71.0–C71.9. Differences in survival by race/ethnicity were examined using univariable and multivariable Cox proportional hazards models. Readmission and mortality outcomes were examined with univariable and multivariable logistic regression.

Results

A total of 1988 patients diagnosed with gliosarcoma were identified (White Non-Hispanic n = 1,682, Black Non-Hispanic n = 165, Asian n = 40, Hispanic n = 101). There were no differences in overall survival, 30- and 90-day mortality, or 30-day readmission between the races and ethnicities examined. Median survival was 10.4 months for White Non-Hispanics (95% CI 9.8, 11.2), 10.2 months for Black Non-Hispanics (95% CI 8.6, 13.1), 9.0 months for Asian Non-Hispanics (95% CI 5.1, 18.2), and 10.6 months for Hispanics (95% CI 8.3,16.2). 7.3% of all patients examined had an unplanned readmission within 30 days.

Conclusion

Race/ethnicity are not associated with differences in overall survival, 30-day mortality, 90-day mortality, or 30-day readmission following surgical intervention for gliosarcoma.
Appendix
Available only for authorised users
Literature
1.
Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol 20(suppl_4):iv1–iv86CrossRefPubMed
2.
Kruchko C, Ostrom QT, Gittleman H, Barnholtz-Sloan JS (2018) The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. Neuro Oncol 20(3):295–298CrossRefPubMedPubMedCentral
3.
Kozak KR, Mahadevan A, Moody JS (2009) Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol 11(2):183–191CrossRefPubMedPubMedCentral
4.
Galanis E, Buckner JC, Dinapoli RP et al (1998) Clinical outcome of gliosarcoma compared with glioblastoma multiforme: north central cancer treatment group results. J Neurosurg 89(3):425–430CrossRefPubMed
5.
Han SJ, Yang I, Ahn BJ et al (2010) Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients. Cancer 116(5):1358–1366CrossRefPubMed
6.
Rath GK, Sharma DN, Mallick S et al (2015) Clinical outcome of patients with primary gliosarcoma treated with concomitant and adjuvant temozolomide: a single institutional analysis of 27 cases. Indian J Cancer 52(4):599–603CrossRefPubMed
7.
8.
Zhang G, Huang S, Zhang J, Wu Z, Lin S, Wang Y (2016) Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients. J Neurooncol 127(2):355–362CrossRefPubMed
9.
10.
Frandsen J, Orton A, Jensen R et al (2018) Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. J Neurosurg 128(4):1133–1138CrossRefPubMed
11.
Barnholtz-Sloan JS, Sloan AE, Schwartz AG (2003) Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer 98(3):603–609CrossRefPubMed
12.
Barnholtz-Sloan JS, Williams VL, Maldonado JL et al (2008) Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 108(4):642–648CrossRefPubMed
13.
Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S (2005) A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer 104(12):2798–2806CrossRefPubMed
14.
Darefsky AS, King JT Jr, Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer 118(8):2163–2172CrossRefPubMed
15.
Ostrom QT, Gittleman H, Fulop J et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 17(Suppl 4):iv1–iv62CrossRefPubMedPubMedCentral
16.
Thakkar JP, Dolecek TA, Horbinski C et al (2014) Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomark Prev 23(10):1985–1996CrossRef
17.
Xu H, Chen J, Xu H, Qin Z (2017) Geographic variations in the incidence of glioblastoma and prognostic factors predictive of overall survival in US Adults from 2004-2013. Front Aging Neurosci 9:352CrossRefPubMedPubMedCentral
18.
Smith DR, Wu CC, Saadatmand HJ et al (2018) Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. J Neurooncol 137(2):303–311CrossRefPubMed
19.
Lerro CC, Robbins AS, Phillips JL, Stewart AK (2013) Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann Surg Oncol 20(6):1759–1765CrossRefPubMed
20.
Bohn A, Braley A, Rodriguez de la Vega P, Zevallos JC, Barengo NC (2018) The association between race and survival in glioblastoma patients in the US: a retrospective cohort study. PLoS ONE 13(6):e0198581CrossRefPubMedPubMedCentral
21.
Srivastava H, Dewan A, Sharma SK et al (2018) Adjuvant radiation therapy and temozolomide in gliosarcoma: is it enough? Case series of seven patients. Asian J Neurosurg 13(2):297–301CrossRefPubMedPubMedCentral
22.
Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS (2018) Adult glioma incidence and survival by race or ethnicity in the United States From 2000 to 2014. JAMA Oncol 4(9):1254–1262CrossRefPubMedPubMedCentral
23.
Brown DA, Himes BT, Kerezoudis P et al (2018) Insurance correlates with improved access to care and outcome among glioblastoma patients. Neuro Oncol 20(10):1374–1382CrossRefPubMedPubMedCentral
24.
Bojko MM, Kucejko RJ, Poggio JL (2018) Racial disparities and the effect of county level income on the incidence and survival of young men with anal cancer. Health Equity 2(1):193–198CrossRefPubMedPubMedCentral
25.
Altman AD, Lambert P, Love AJ et al (2017) Examining the effects of time to diagnosis, income, symptoms, and incidental detection on overall survival in epithelial ovarian cancer: manitoba ovarian cancer outcomes (MOCO) study group. Int J Gynecol Cancer. 27(8):1637–1644CrossRefPubMed
26.
Steenland K, Rodriguez C, Mondul A, Calle EE, Thun M (2004) Prostate cancer incidence and survival in relation to education (United States). Cancer Causes Control 15(9):939–945CrossRefPubMed
27.
Smailyte G, Jasilionis D, Vincerzevskiene I, Shkolnikov VM (2016) Education, survival, and avoidable deaths in Lithuanian cancer patients, 2001-2009. Acta Oncol 55(7):859–864CrossRefPubMed
28.
de Vries E, Uribe C, Pardo C, Lemmens V, Van de Poel E, Forman D (2015) Gastric cancer survival and affiliation to health insurance in a middle-income setting. Cancer Epidemiol 39(1):91–96CrossRefPubMed
29.
Hussain SK, Altieri A, Sundquist J, Hemminki K (2008) Influence of education level on breast cancer risk and survival in Sweden between 1990 and 2004. Int J Cancer 122(1):165–169CrossRefPubMed
30.
Hussain SK, Lenner P, Sundquist J, Hemminki K (2008) Influence of education level on cancer survival in Sweden. Ann Oncol 19(1):156–162CrossRefPubMed
31.
Brusselaers N, Ljung R, Mattsson F et al (2013) Education level and survival after oesophageal cancer surgery: a prospective population-based cohort study. BMJ Open 3(12):e003754CrossRefPubMedPubMedCentral
32.
Ansell D, Whitman S, Lipton R, Cooper R (1993) Race, income, and survival from breast cancer at two public hospitals. Cancer 72(10):2974–2978CrossRefPubMed
33.
Vincerzevskiene I, Jasilionis D, Austys D, Stukas R, Kaceniene A, Smailyte G (2017) Education predicts cervical cancer survival: a Lithuanian cohort study. Eur J Public Health 27(3):421–424PubMed
34.
Herndon JE 2nd, Kornblith AB, Holland JC, Paskett ED (2008) Patient education level as a predictor of survival in lung cancer clinical trials. J Clin Oncol 26(25):4116–4123CrossRefPubMedPubMedCentral
35.
Herndon JE 2nd, Kornblith AB, Holland JC, Paskett ED (2013) Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials. Psychooncology 22(2):315–323PubMed
36.
Boyd C, Zhang-Salomons JY, Groome PA, Mackillop WJ (1999) Associations between community income and cancer survival in Ontario, Canada, and the United States. J Clin Oncol 17(7):2244–2255CrossRefPubMed
37.
Dalton SO, Steding-Jessen M, Gislum M, Frederiksen K, Engholm G, Schuz J (2008) Social inequality and incidence of and survival from cancer in a population-based study in Denmark, 1994-2003: background, aims, materials and methods. Eur J Cancer 44(14):1938–1949CrossRefPubMed
38.
Gorey KM (2009) Breast cancer survival in Canada and the USA: meta-analytic evidence of a Canadian advantage in low-income areas. Int J Epidemiol 38(6):1543–1551CrossRefPubMedPubMedCentral
39.
Gorey KM, Fung KY, Luginaah IN, Holowaty EJ, Hamm C (2010) Income and long-term breast cancer survival: comparisons of vulnerable urban places in Ontario and California. Breast J 16(4):416–419PubMedPubMedCentral
40.
Gorey KM, Kanjeekal SM, Wright FC et al (2015) Colon cancer care and survival: income and insurance are more predictive in the USA, community primary care physician supply more so in Canada. Int J Equity Health 14:109CrossRefPubMedPubMedCentral
41.
Bajaj A, Martin B, Bhasin R et al (2018) The impact of academic facility type and case volume on survival in patients undergoing curative radiation therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 100(4):851–857CrossRefPubMed
42.
Cheraghlou S, Kuo P, Judson BL (2017) Treatment delay and facility case volume are associated with survival in early-stage glottic cancer. Laryngoscope 127(3):616–622CrossRefPubMed
43.
Baade PD, Dasgupta P, Aitken JF, Turrell G (2011) Distance to the closest radiotherapy facility and survival after a diagnosis of rectal cancer in Queensland. Med J Aust 195(6):350–354CrossRefPubMed
44.
Chen YW, Mahal BA, Muralidhar V et al (2016) Association between treatment at a high-volume facility and improved survival for radiation-treated men with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 94(4):683–690CrossRefPubMed
45.
Koshy M, Malik R, Mahmood U, Husain Z, Sher DJ (2015) Stereotactic body radiotherapy and treatment at a high volume facility is associated with improved survival in patients with inoperable stage I non-small cell lung cancer. Radiother Oncol 114(2):148–154CrossRefPubMed
46.
Boffa DJ, Rosen JE, Mallin K et al (2017) Using the national cancer database for outcomes research: a review. JAMA Oncol 3(12):1722–1728CrossRefPubMed
Metadata
Title
Racial/ethnic differences in survival for patients with gliosarcoma: an analysis of the National cancer database
Authors
James M. Wright
Tiffany R. Hodges
Christina Huang Wright
Haley Gittleman
Xiaofei Zhou
Kelsey Duncan
Carol Kruchko
Andrew Sloan
Jill S. Barnholtz-Sloan
Publication date
01-06-2019
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2019
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-019-03170-7

Other articles of this Issue 2/2019

Journal of Neuro-Oncology 2/2019 Go to the issue

Laboratory Investigation

Correlation of the invasive potential of glioblastoma and expression of caveola-forming proteins caveolin-1 and CAVIN1

Clinical Study

Outcomes of large vestibular schwannomas following subtotal resection: early post-operative volume regression and facial nerve function

Clinical Study

Diagnostic delay and morbidity of central nervous system tumors in children and young adults: a pediatric hospital experience

Laboratory Investigation

Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours

Laboratory Investigation

Identification of PEPT2 as an important candidate molecule in 5-ALA-mediated fluorescence-guided surgery in WHO grade II/III gliomas

Topic Review

Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis